Cairn Therapeutics
  • About
  • CT-262
  • Opportunity
  • Contact

Our Goal:

Develop a new class of compounds that selectively kill cancer cells by exploiting a difference in the microenvironments between cancer cells and healthy cells.

​Our distinctive approach provides broad applicability across different tumor types.

  • We use unique medicinal chemistry to design non-toxic prodrugs that remain inactive until they enter cancer cells, where they are selectively activated to allow DNA binding and alkylation, leading to cell death
​​
  • ​Our lead compound (CT-262) has completed preclinical development studies and is on the verge of entering clinical studies to provide proof of concept for this class of drugs

Investment Highlights

  • Highly focused team with extensive pharmaceutical industry expertise
​​
  • Patent protection: Exclusive, worldwide license agreement with TSRI for the CT-262 patent estate
 
  • Potential near-term value inflection points

  • New class of compounds leading to potential major advance in the treatment of cancer
Copyright © Cairn 2023
  • About
  • CT-262
  • Opportunity
  • Contact